What is the treatment for initial and recurrent Herpes Simplex Type 1 (Hs1)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for HSV-1 Infection: Initial and Recurrent Episodes

For HSV-1 infections, oral antiviral medications including valacyclovir, acyclovir, and famciclovir are the mainstay of treatment, with different regimens recommended for initial versus recurrent episodes. 1

Initial Episode Treatment

  • For first clinical episodes of HSV-1 infection, longer treatment courses are recommended 2:

    • Valacyclovir 1 g orally twice daily for 7-10 days 1
    • Acyclovir 400 mg orally three times daily for 7-10 days 2
    • Acyclovir 200 mg orally five times daily for 7-10 days 2
    • Famciclovir 250 mg orally three times daily for 7-10 days 2
  • Treatment may be extended if healing is incomplete after 10 days of therapy 2

  • Higher dosages of acyclovir (400 mg orally five times a day) may be used for first-episode oral infections, including stomatitis or pharyngitis 2

Recurrent Episode Treatment

  • For recurrent episodes, shorter treatment courses are recommended 2:

    • Valacyclovir 500 mg orally twice daily for 5 days 1
    • Acyclovir 400 mg orally three times daily for 5 days 2
    • Acyclovir 800 mg orally twice daily for 5 days 2
    • Acyclovir 200 mg orally five times daily for 5 days 2
    • Famciclovir 125 mg orally twice daily for 5 days 2
  • Treatment is most effective when started during the prodromal period or within 1 day after onset of lesions 2, 3

  • Patients should be provided with medication or a prescription to initiate treatment at the first sign of prodrome or lesions 2

  • Delayed treatment beyond 72 hours significantly reduces effectiveness 3

Suppressive Therapy

  • Daily suppressive therapy should be considered for patients with frequent recurrences (≥6 episodes per year) 2, 1

  • Recommended suppressive regimens include 2:

    • Acyclovir 400 mg orally twice daily 2
    • Famciclovir 250 mg orally twice daily 2
    • Valacyclovir 250 mg orally twice daily 2
    • Valacyclovir 500 mg orally once daily 2
    • Valacyclovir 1,000 mg orally once daily 2
  • Suppressive therapy reduces the frequency of genital herpes recurrences by ≥75% among patients with frequent recurrences 2

  • After 1 year of continuous suppressive therapy, discontinuation should be considered to assess the patient's recurrence rate 2

Important Clinical Considerations

  • Topical acyclovir is substantially less effective than systemic therapy and is not recommended 1, 4

  • Systemic antiviral drugs partially control symptoms but do not eradicate latent virus or affect subsequent recurrences after discontinuation 2, 1

  • HSV-1 causes 5-30% of first-episode genital herpes cases, but clinical recurrences are much less frequent for HSV-1 than HSV-2 genital infection 2

  • Patient counseling is essential and should include information about 2:

    • Natural history of HSV infection
    • Potential for recurrent episodes and asymptomatic viral shedding
    • Sexual transmission risk
    • Methods to reduce transmission (abstaining during outbreaks, condom use)

Special Populations

  • HIV-infected patients with HSV should be monitored closely as they may require longer courses of therapy than HIV-negative patients 2, 1

  • For immunocompromised patients, higher doses or longer courses of antivirals may be needed 5

  • For pregnant women, safety considerations are important - ciprofloxacin is contraindicated during pregnancy 2

  • For severe disease or complications requiring hospitalization, intravenous therapy may be necessary 5

Treatment Failure Considerations

  • If symptoms persist beyond expected healing time, consider incorrect diagnosis, co-infection with another STD, HIV infection, poor medication adherence, or antiviral resistance 1

  • For acyclovir-resistant HSV, which is rare in immunocompetent patients but more common in immunocompromised hosts, IV foscarnet is the treatment of choice 6

References

Guideline

Treatment for Herpes Simplex 2 (Genital Herpes)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for Genital Herpes Simplex Virus Outbreaks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Suspected HSV with History of HSV-1 Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.